Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas

Purpose: Cytokine therapies such as IL2 and IL12 suffer from impractically small therapeutic windows driven by their on-target, off-tumor activity, limiting their clinical potential despite potent antitumor effects. We previously engineered cytokines that bind and anchor to tumor collagen following intratumoral injection, and sought to test their safety and biomarker activity in spontaneous canine soft-tissue sarcomas (STS).Experimental Design: Collagen-binding cytokines were canine-ized to minimize immunogenicity and were used in a rapid dose-escalation study in healthy beagles to identify a maximum tolerated dose. Ten client-owned pet dogs with STS were then enrolled into trial, receiving cytokines at different intervals prior to surgical tumor excision. Tumor tissue was analyzed through IHC and NanoString RNA proflling for dynamic changes within treated tumors. Archived, untreated STS samples were analyzed in parallel as controls.Results: Intratumorally administered collagen-binding IL2 and IL12 were well tolerated by STS-bearing dogs, with only Grade 1/2 adverse events observed (mild fever, thrombocytopenia, neutrope-nia). IHC revealed enhanced T-cell inflltrates, corroborated by an enhancement in gene expression associated with cytotoxic immune function. We found concordant increases in expression of counter-regulatory genes that we hypothesize would contribute to a transient antitumor effect, and conflrmed in mouse models that combination therapy to inhibit this counter-regulation can improve responses to cytokine therapy.Conclusions: These results support the safety and activity of intratumorally delivered, collagen-anchoring cytokines for inflam-matory polarization of the canine STS tumor microenvironment. We are further evaluating the efflcacy of this approach in additional canine cancers, including oral malignant melanoma.

Automated summary

In this study, the safety and biomarker activity of cytokine therapy were tested in spontaneous canine soft-tissue sarcomas. The results showed that intratumorally administered collagen-binding cytokines can enhance T-cell infiltration and increase gene expression associated with cytotoxic immune function. These findings support the safety and activity of this therapeutic approach for inflammatory polarization of the tumor microenvironment in canine STS.